Efficacy of triazoles in a murine disseminated infection by Candida krusei

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3585-3588

  Mariné, Marçal ^a   Pastor, F Javier ^a   Serena, Carolina ^a   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; POSACONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA KRUSEI; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; KIDNEY PARENCHYMA; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL RATE; TREATMENT DURATION;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; KIDNEY; MALE; MICE; PYRIMIDINES; RANDOM ALLOCATION; TRIAZOLES;

EID: 67749124367     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00293-09     Document Type: Article

References (26)

1. Espinel-Ingroff, A., E. Cantón, J. Pemán, and M. Gobernado. 2002. Fungicidal activity of voriconazole against Candida krusei by time-kill curves. Proceedings of the 8th Congress of the European Confederation of Medical Mycology, Budapest, Hungary.
2. Isham, N. C., and M. A. Ghannoum. 2007. Voriconazole and caspofungin cidality against non-albicans Candida spp. Infect. Dis. Clin. Pract. 15:250-253.
3. Kullberg, B. J., J. D. Sobel, M. Ruhnke, P. G. Pappas, C. Viscoli, J. H. Rex, J. D. Cleary, E. Rubinstein, L. W. Church, J. M. Brown, H. T. Schlamm, I. T. Oborska, F. Hilton, and M. R. Hodges. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435-1442.
4. Lozano-Chiu, M., S. Arikan, V. L. Paetznick, E. J. Anaissie, D. Loebenberg, and J. H. Rex. 1999. Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. 43:589-591.
5. Majithiya, J., A. Sharp, A. Parmar, D. W. Denning, and P. A. Warn. 2009. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J. Antimicrob. Chemother. 63:161-166.
6. Mariné, M., C. Serena, B. Fernández-Torres, F. J. Pastor, and J. Guarro. 2005. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata. Antimicrob. Agents Chemother. 49:4757-4759.
7. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility of yeasts. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
8. Nomeir, A. A., P. Kumari, M. J. Hilbert, S. Gupta, D. Loebenberg, A. Cacciapuoti, R. Hare, G. H. Miller, C. C. Lin, and M. N. Cayen. 2000. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob. Agents Chemother. 44:727-731.
9. Ortoneda, M., J. Capilla, F. J. Pastor, I. Pujol, and J. Guarro. 2002. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob. Agents Chemother. 46:2273-2275.
10. Ostrosky-Zeichner, L., M. A. Oude Lashof, B. J. Kullberg, and J. H. Rex. 2003. Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 22:651-655.
11. Pastor, F. J., and J. Guarro. 2007. The role of voriconazole in the treatment of emerging mycoses. Rev. Iberoam. Micol. 24:228-232.
12. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, J. F. Meis, I. M. Gould, W. Fu, A. L. Colombo, E. Rodriguez-Noriega, and the Global Antifungal Surveillance Study. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45:1735-1745.
13. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, E. Nagy, S. Dobiasova, M. Rinaldi, R. Barton, A. Veselov, and the Global Antifungal Surveillance Group. 2008. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46:515-521.
14. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. 42:3137-3141.
15. Pfaller, M. A., P. G. Pappas, and J. R. Wingard. 2006. Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis. 43:S3-S14.
16. Pfaller, M. A., D. J. Sheehan, and J. H. Rex. 2004. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17:268-280.
17. Quindós, G., L. O. Sánchez-Vargas, M. Villar-Vidal, E. Eraso, M. Alkorta, and J. L. Hernández-Almaraz. 2008. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Int. J. Antimicrob. Agents 31:266-271.
18. Rodríguez, M. M., E. Calvo, C. Serena, M. Mariné, F. J. Pastor, and J. Guarro. 2009. Effect of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob. Agents Chemother. 53:2153-2155.
19. Rodríguez, M. M., F. J. Pastor, C. Serena, and J. Guarro. 2009. Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus. J. Antimicrob. Chemother. 63:361-364.
20. Roffey, S. J., S. Cole, P. Comby, D. Gibson, S. G. Jezequel, A. N. Nedderman, D. A. Smith, D. K. Walker, and N. Wood. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31:731-741.
21. Rubio, M. C., I. R. de Ocáriz, J. Gil, R. Benito, and A. Rezusta. 2005. Potential fungicidal effect of voriconazole against Candida spp. Int. J. Antimicrob. Agents 25:264-267.
22. Serena, C., F. J. Pastor, M. Mariné, M. M. Rodríguez, and J. Guarro. 2007. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J. Antimicrob. Chemother. 60:162-165.
23. Sóczó, G., G. Kardos, P. M. McNicholas, E. Balogh, L. Gergely, I. Varga, B. Kelentey, and L. Majoros. 2007. Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species. J. Antimicrob. Chemother. 60:1004-1009.
24. Spellberg, B. J., S. G. Filler, and J. E. Edwards, Jr. 2006. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 42:244-251.
25. Sugar, A. M., and X. P. Liu. 2000. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med. Mycol. 38:209-212.
26. Theuretzbacher, U., F. Ihle, and H. Derendorf. 2006. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663.